Cytotoxic chemotherapy: Advances in delivery, pharmacology, and testing

Current oncology reports

Volumn 2, Issue 5, 2000, Pages 445-453

  Ciordia, Roberto ^a   Supko, Jeffrey ^a   Gatineau, Michel ^a   Batchelor, Tracy ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BLOOD BRAIN BARRIER; BRAIN TUMOR; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG INTERACTION; GLIOMA; HUMAN; REVIEW;

ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; DRUG INTERACTIONS; GLIOMA; HUMANS;

EID: 0034277628     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-000-0065-1     Document Type: Review

References (63)

1. 1. E Harras 1996 Cancer Rates and Risks edn 4 National Institutes of Health, National Cancer Institute Bethesda, MD Harras E (Ed): Cancer Rates and Risks, edn 4. Bethesda, MD: National Institutes of Health, National Cancer Institute; 1996.
2. 2. HA Fine KB Dear JS Loeffler 1993 Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults Cancer 71 2585 2597 8453582 10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO;2-S 1:STN:280:DyaK3s3gtFCrtQ%3D%3D Fine HA, Dear KB, Loeffler JS, et al.: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993, 71:2585–2597.
3. 3. FH Hochberg A Pruitt 1980 Assumptions in the radiotherapy of glioblastoma Neurology 30 907 911 6252514 1:STN:280:DyaL3M%2FjtFantg%3D%3D Hochberg FH, Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurology 1980, 30:907–911.
4. 4. VA Levin PM Kabra MA Freeman-Dove 1978 Pharmacokinetics of intracarotid artery 14C-BCNU in the squirrel monkey J Neurosurg 48 587 593 416182 1:CAS:528:DyaE1cXktVSit7s%3D Levin VA, Kabra PM, Freeman-Dove MA: Pharmacokinetics of intracarotid artery 14C-BCNU in the squirrel monkey. J Neurosurg 1978, 48:587–593.
5. 5. K Yamada Y Ushio T Hayakawa 1987 Distribution of radiolabeled 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride in rat brain tumor: intraarterial versus intravenous administration Cancer Res 47 2123 2128 3470138 1:CAS:528:DyaL2sXktlamsLc%3D Yamada K, Ushio Y, Hayakawa T, et al.: Distribution of radiolabeled 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride in rat brain tumor: intraarterial versus intravenous administration. Cancer Res 1987, 47:2123–2128.
6. 6. DE Bullard SH Bigner DD Bigner 1985 Comparison of intravenous versus intracarotid therapy with 1,3-bis (2-chloroethyl)-1-nitrosourea in a rat brain tumor model Cancer Res 45 5240 5245 4053004 1:CAS:528:DyaL2MXmtVGrtLw%3D Bullard DE, Bigner SH, Bigner DD: Comparison of intravenous versus intracarotid therapy with 1,3-bis (2-chloroethyl)-1-nitrosourea in a rat brain tumor model. Cancer Res 1985, 45:5240–5245.
7. 7. WR Shapiro SB Green PC Burger 1992 A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma J Neurosurg 76 772 81 1564540 1:STN:280:DyaK383is1yhsA%3D%3D Report from an important multicenter, randomized phase III study of intra-arterial versus iv BCNU with or without 5-fluorouracil. No improvement was seen in the intra-arterial treatment group, and toxicity was increased Shapiro WR, Green SB, Burger PC, et al.: A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 1992, 76:772–81. Report from an important multicenter, randomized phase III study of intra-arterial versus iv BCNU with or without 5-fluorouracil. No improvement was seen in the intra-arterial treatment group, and toxicity was increased.
8. 8. M Tamaki K Ohno Y Niimi 1997 Parenchymal damage in the territory of the anterior choroidal artery following supraophthalmic intracarotid administration of CDDP for treatment of malignant gliomas J Neurooncol 35 65 72 9266442 10.1023/A:1005847115488 1:STN:280:DyaK2svhtFCltg%3D%3D Tamaki M, Ohno K, Niimi Y, et al.: Parenchymal damage in the territory of the anterior choroidal artery following supraophthalmic intracarotid administration of CDDP for treatment of malignant gliomas. J Neurooncol 1997, 35:65–72.
9. 9. BV Zlokovic ML Apuzzo 1998 Strategies to circumvent vascular barriers of the central nervous system [editorial; comment] Neurosurgery 43 877 878 9766315 10.1097/00006123-199810000-00089 1:STN:280:DyaK1cvjslOjtw%3D%3D Zlokovic BV, Apuzzo ML: Strategies to circumvent vascular barriers of the central nervous system [editorial; comment]. Neurosurgery 1998, 43:877–878.
10. 10. RA Kroll EA Neuwelt 1998 Outwitting the blood brain barrier for therapeutic purposes: osmotic opening and other means Neurosurgery 42 1083 1100 9588554 10.1097/00006123-199805000-00082 1:STN:280:DyaK1c3ksl2lug%3D%3D A comprehensive review of the physiology of the blood-brain barrier and methods that have been developed to improve delivery of drugs to brain tumors Kroll RA, Neuwelt EA: Outwitting the blood brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998, 42:1083–1100. A comprehensive review of the physiology of the blood-brain barrier and methods that have been developed to improve delivery of drugs to brain tumors.
11. 11. MK Gumerlock EA Neuwelt 1992 Chemotherapy of brain tumors: innovative approaches RA Morantz JW Walsh Brain Tumors Marcel Dekker New York 763 778 Gumerlock MK, Neuwelt EA: Chemotherapy of brain tumors: innovative approaches. In Brain Tumors. Edited by Morantz RA, Walsh JW. New York: Marcel Dekker 1992:763–778.
12. 12. EA Neuwelt J Hourieson EP Frenkel 1986 Therapeutic efficacy of multi-agent chemotherapy with drug delivery enhancement by blood brain barrier modification in glioblastomas Neurosurgery 19 573 582 3097567 10.1097/00006123-198610000-00011 1:STN:280:DyaL2s%2FmsFGiug%3D%3D Neuwelt EA, Hourieson J, Frenkel EP, et al.: Therapeutic efficacy of multi-agent chemotherapy with drug delivery enhancement by blood brain barrier modification in glioblastomas. Neurosurgery 1986, 19:573–582.
13. 13. J Ford C Osborn T Barton NM Bleehen 1998 A phase I study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma Eur J Cancer 34 1807 1811 9893673 10.1016/S0959-8049(98)00155-5 1:CAS:528:DyaK1cXntlShu7o%3D Ford J, Osborn C, Barton T, Bleehen NM: A phase I study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma. Eur J Cancer 1998, 34:1807–1811.
14. 14. TF Cloughesy KL Black YP Gobin 1999 Intra-arterial Ceroport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas Neurosurgery 44 270 278 9932880 10.1097/00006123-199902000-00015 1:STN:280:DyaK1M7ivFKlsg%3D%3D Cloughesy TF, Black KL, Gobin YP, et al.: Intra-arterial Ceroport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas. Neurosurgery 1999, 44:270–278.
15. 15. HA Fine KH Antman 1992 High-dose chemotherapy with autologous bone marrow transplantation in the treatment of high grade astrocytomas in adults: therapeutic rationale and clinical experience Bone Marrow Transplant 10 315 321 1330152 1:STN:280:DyaK3s%2FksFShsg%3D%3D Fine HA, Antman KH: High-dose chemotherapy with autologous bone marrow transplantation in the treatment of high grade astrocytomas in adults: therapeutic rationale and clinical experience. Bone Marrow Transplant 1992, 10:315–321.
16. 16. OA Fernandez-Hidalgo V Vanaclocha JM Vieitez 1996 Highdose BCNU and autologous progenitor cell transplantation given with intra-arterial cisplatinum and simultaneous radiotherapy in the treatment of high-grade gliomas: benefit for selected patients Bone Marrow Transplant 18 143 149 8832007 1:STN:280:DyaK28vivV2jtw%3D%3D Fernandez-Hidalgo OA, Vanaclocha V, Vieitez JM, et al.: Highdose BCNU and autologous progenitor cell transplantation given with intra-arterial cisplatinum and simultaneous radiotherapy in the treatment of high-grade gliomas: benefit for selected patients. Bone Marrow Transplant 1996, 18:143–149.
17. 17. EK Mbidde PJ Selby TJ Perren 1988 High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma Br J Cancer 58 779 782 2852028 1:STN:280:DyaL1M7jsVKrsw%3D%3D Mbidde EK, Selby PJ, Perren TJ, et al.: High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma. Br J Cancer 1988, 58:779–782.
18. 18. S Bakhshi RB North 1995 Implantable pumps for drug delivery to the brain J Neurooncol 26 133 139 8787855 10.1007/BF01060219 1:STN:280:DyaK28znvFynsA%3D%3D Bakhshi S, North RB: Implantable pumps for drug delivery to the brain. J Neurooncol 1995, 26:133–139.
19. 19. RE Harbaugh 1989 Novel CNS-directed drug delivery systems in Alzheimer’s disease and other neurological disorders Neurobiol Aging 10 623 629 2572986 10.1016/0197-4580(89)90155-3 1:STN:280:DyaK3c%2FksVGntA%3D%3D Harbaugh RE: Novel CNS-directed drug delivery systems in Alzheimer’s disease and other neurological disorders. Neurobiol Aging 1989, 10:623–629.
20. 20. MC Chamberlain P Kormanik SB Howell 1995 Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases Arch Neurol 52 912 917 7661730 1:STN:280:DyaK2MzptVygtw%3D%3D Chamberlain MC, Kormanik P, Howell SB, et al.: Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol 1995, 52:912–917.
21. 21. RG Blasberg C Patlak JD Fenstermacher 1975 Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion J Pharmacol Exp Ther 195 73 83 810575 1:CAS:528:DyaE2MXlslagu7o%3D Blasberg RG, Patlak C, Fenstermacher JD: Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 1975, 195:73–83.
22. 22. MC Chamberlain 1998 Leptomeningeal metastases: a review of evaluation and treatment J Neurooncol 37 271 284 9524085 10.1023/A:1005976926058 1:STN:280:DyaK1c7ot1alsg%3D%3D Chamberlain MC: Leptomeningeal metastases: a review of evaluation and treatment. J Neurooncol 1998, 37:271–284.
23. 23. EP Sipos H Brem 1995 New delivery systems for brain tumor therapy Neurol Clin 13 813 825 8583998 1:STN:280:DyaK287lsl2hsg%3D%3D Sipos EP, Brem H: New delivery systems for brain tumor therapy. Neurol Clin 1995, 13:813–825.
24. 24. WL Walker J Cook 1996 Drug delivery to brain tumors Bull Math Biol 58 1047 1074 8953256 10.1007/BF02458383 1:STN:280:DyaK2s7htFertg%3D%3D Walker WL, Cook J: Drug delivery to brain tumors. Bull Math Biol 1996, 58:1047–1074.
25. 25. H Brem A Kader JI Epstein 1989 Biocompatibility of a biodegradable, controlled-release polymer in the rabbit brain Sel Cancer Ther 5 55 65 2772427 1:CAS:528:DyaL1MXkvVequ78%3D Brem H, Kader A, Epstein JI, et al.: Biocompatibility of a biodegradable, controlled-release polymer in the rabbit brain. Sel Cancer Ther 1989, 5:55–65.
26. 26. KW Leong PD D’Amore M Marletta R Langer 1986 Bioerodible polyanhydrides as drug-carrier matrices. II. Biocompatibility and chemical reactivity J Biomed Mater Res 20 51 64 3949823 10.1002/jbm.820200106 1:CAS:528:DyaL28XitFejurk%3D Leong KW, D’Amore PD, Marletta M, Langer R: Bioerodible polyanhydrides as drug-carrier matrices. II. Biocompatibility and chemical reactivity. J Biomed Mater Res 1986, 20:51–64.
27. 27. SA Grossman C Reinhard OM Colvin 1992 The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers J Neurosurg 76 640 647 1545259 1:CAS:528:DyaK38XisVWrt7g%3D 10.3171/jns.1992.76.4.0640 Grossman SA, Reinhard C, Colvin OM, et al.: The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg 1992, 76:640–647.
28. 28. MB Yang RJ Tamargo H Brem 1989 Controlled delivery of 1,3-bis(2-chloroethyl)-1-nitrosourea from ethylene-vinyl acetate copolymer Cancer Res 49 5103 5107 2766281 1:CAS:528:DyaL1MXlvVSmtbc%3D Yang MB, Tamargo RJ, Brem H: Controlled delivery of 1,3-bis(2-chloroethyl)-1-nitrosourea from ethylene-vinyl acetate copolymer. Cancer Res 1989, 49:5103–5107.
29. 29. H Brem S Piantadosi PC Burger 1995 Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas: the Polymer-brain Tumor Treatment Group Lancet 345 1008 1012 7723496 10.1016/S0140-6736(95)90755-6 1:STN:280:DyaK2M3ktVansw%3D%3D Brem H, Piantadosi S, Burger PC, et al.: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas: the Polymer-brain Tumor Treatment Group. Lancet 1995, 345:1008–1012.
30. 30. H Brem MS Mahaley Jr. NA Vick 1991 Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas J Neurosurg 74 441 446 1993909 1:STN:280:DyaK3M7jt1aluw%3D%3D Brem H, Mahaley MS, Jr., Vick NA, et al.: Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991, 74:441–446.
31. 31. H Brem MG Ewend S Piantadosi 1995 The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial J Neurooncol 26 111 123 8787853 10.1007/BF01060217 1:STN:280:DyaK28znvFynsg%3D%3D Brem H, Ewend MG, Piantadosi S, et al.: The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J Neurooncol 1995, 26:111–123.
32. 32. S Valtonen U Timonen P Toivanen 1997 Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study Neurosurgery 41 44 49 9218294 10.1097/00006123-199707000-00011 1:STN:280:DyaK2szmtFCjsg%3D%3D Valtonen S, Timonen U, Toivanen P, et al.: Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997, 41:44–49.
33. 33. A Olivia F Barker S Tatter 2000 Results of a phase I study of interstitial BCNV admininstered via wafers to patients with recurrent glioma. [abstract Proc ASCO 19 160a 160a Olivia A, Barker F, Tatter S, et al.: Results of a phase I study of interstitial BCNV admininstered via wafers to patients with recurrent glioma. [abstract ] Proc ASCO 2000, 19:160a.
34. 34. DR Groothuis 2000 The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery Neuro-oncology 2 45 59 11302254 10.1215/15228517-2-1-45 1:STN:280:DC%2BD3M3jsF2htw%3D%3D A review of strategies for increasing drug delivery to brain tumors with an emphasis on potential barriers to drug distribution within brain parenchyma and the method of convection-enhanced delivery Groothuis DR: The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro-oncology Jan 2000, 2:45–59. A review of strategies for increasing drug delivery to brain tumors with an emphasis on potential barriers to drug distribution within brain parenchyma and the method of convection-enhanced delivery.
35. 35. DR Groothuis H Benalcazar CV Allen 2000 Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration Brain Res 856 281 290 10677637 10.1016/S0006-8993(99)02089-2 1:CAS:528:DC%2BD3cXhtFanu7o%3D Groothuis DR, Benalcazar H, Allen CV, et al.: Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration. Brain Res 2000, 856:281–290.
36. 36. DW Laske RJ Youle EH Oldfield 1997 Tumor regression with regional distribution of the targeted toxin TF-CRM 107 in patients with malignant brain tumors Nature Med 3 1362 1368 9396606 10.1038/nm1297-1362 1:CAS:528:DyaK2sXnvVGisrw%3D Laske DW, Youle RJ, Oldfield EH: Tumor regression with regional distribution of the targeted toxin TF-CRM 107 in patients with malignant brain tumors. Nature Med 1997, 3:1362–1368.
37. 37. NH Greig 1988 Drug delivery to the brain A Neuwelt Blood-brain Barrier Plenum New York 322 322 Greig NH. Drug delivery to the brain. In Blood-brain Barrier. Edited by Neuwelt A. New York: Plenum; 1988:322.
38. 38. MG Donelli M Zucchetti M D’Incalci 1992 Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 30 251 260 1643692 10.1007/BF00686291 1:STN:280:DyaK38zlsVWjtQ%3D%3D Donelli MG, Zucchetti M, D’Incalci M: Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 1992, 30:251–260.
39. 39. DJ Stewart 1994 A critique of the role of the blood-brain barrier i the chemotherapy of human brain tumors J Neurooncol 20 121 139 7807190 10.1007/BF01052723 1:STN:280:DyaK2M7gsF2isw%3D%3D Stewart DJ: A critique of the role of the blood-brain barrier i the chemotherapy of human brain tumors. J Neurooncol 1994, 20:121–139.
40. 40. EC Lange de M Danhof AG Boer de 1997 Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier Brain Res Rev 25 27 49 9370049 10.1016/S0165-0173(97)00014-3 de Lange EC, Danhof M, de Boer AG, et al.: Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier. Brain Res Rev 1997, 25:27–49.
41. 41. M Muller RM Mader B Steiner 1997 5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients Cancer Res 57 2598 2601 9205062 1:CAS:528:DyaK2sXkt12ru7k%3D Muller M, Mader RM, Steiner B, et al.: 5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients. Cancer Res 1997, 57:2598–2601.
42. 42. L Persson J Valtysson P Enblad 1996 Neurochemical monitoring using intracerebral microdialysis in patients with subarachnoid hemorrhage J Neurosurg 84 606 616 8613852 1:STN:280:DyaK287otVagtg%3D%3D 10.3171/jns.1996.84.4.0606 Persson L, Valtysson J, Enblad P, et al.: Neurochemical monitoring using intracerebral microdialysis in patients with subarachnoid hemorrhage. J Neurosurg 1996, 84:606–616.
43. 43. D Devineni A Klein-Szanto JM Gallo 1996 In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats Cancer Chemother Pharmacol 38 499 507 8823490 10.1007/s002800050518 1:CAS:528:DyaK28XmsVGqsLg%3D Devineni D, Klein-Szanto A, Gallo JM. In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats. Cancer Chemother Pharmacol 1996, 38:499–507.
44. 44. TM Rudkin DL Arnold 1999 Proton magnetic resonance spectroscopy for the diagnosis and management of cerebral disorders Arch Neurol 56 919 926 10448796 10.1001/archneur.56.8.919 1:STN:280:DyaK1Mzns1ShtA%3D%3D Rudkin TM, Arnold DL: Proton magnetic resonance spectroscopy for the diagnosis and management of cerebral disorders. Arch Neurol 1999, 56:919–926.
45. 45. W Wolf V Waluch CA Presant 1998 Non-invasive 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies NMR Biomed 11 380 387 9859944 10.1002/(SICI)1099-1492(1998110)11:7<380::AID-NBM517>3.0.CO;2-Q 1:CAS:528:DyaK1MXmtVSl Wolf W, Waluch V, Presant CA: Non-invasive 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies. NMR Biomed 1998, 11:380–387.
46. 46. JL Tyler YL Yamamoto M Diksic 1986 Pharmacokinetics of superselective intra-arterial and intravenous 11C-BCNU evaluated by PET J Nucl Med 27 775 780 3486962 1:STN:280:DyaL283is1Kltg%3D%3D Tyler JL, Yamamoto YL, Diksic M, et al.: Pharmacokinetics of superselective intra-arterial and intravenous 11C-BCNU evaluated by PET. J Nucl Med 1986, 27:775–780.
47. 47. M Diksic K Sako W Feindel 1984 Pharmacokinetics of positron-labeled 1,3-bis(2-chloroethyl)nitrosourea in human brain tumors using positron emission tomography Cancer Res 44 3120 3124 6609769 1:STN:280:DyaL2c3gsFCqtA%3D%3D Diksic M, Sako K, Feindel W, et al.: Pharmacokinetics of positron-labeled 1,3-bis(2-chloroethyl)nitrosourea in human brain tumors using positron emission tomography. Cancer Res 1984, 44:3120–3124.
48. 48. JZ Ginos AJ Cooper V Dhawan 1987 [13N]-cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors J Nucl Med 28 1844 1852 3500286 1:CAS:528:DyaL1MXptFertg%3D%3D Ginos JZ, Cooper AJ, Dhawan V, et al.: [13N]-cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. J Nucl Med 1987, 28:1844–1852.
49. 49. J Kissel G Brix ME Bellemann 1997 Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma Cancer Res 57 3415 3423 9270007 1:CAS:528:DyaK2sXls1Shuro%3D Kissel J, Brix G, Bellemann ME, et al.: Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Res 1997, 57:3415–3423.
50. 50. SR Meikle JC Matthews CS Brock 1998 Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study Cancer Chemother Pharmacol 42 183 193 9685053 10.1007/s002800050804 1:CAS:528:DyaK1cXks1yiur0%3D Meikle SR, Matthews JC, Brock CS, et al.: Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study. Cancer Chemother Pharmacol 1998, 42:183–193.
51. 51. E Meerten van J Verweij JH Schellens 1995 Antineoplastic agents: drug interactions of clinical significance Drug Saf 12 168 182 7619329 van Meerten E, Verweij J, Schellens JH: Antineoplastic agents: drug interactions of clinical significance. Drug Saf 1995, 12:168–182.
52. 52. HL McLeod 1998 Clinically relevant drug-drug interactions in oncology Br J Clin Pharmacol 45 539 544 9663808 10.1046/j.1365-2125.1998.00719.x 1:CAS:528:DyaK1cXktFaitrs%3D McLeod HL: Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol 1998, 45:539–544.
53. 53. MR Fetell SA Grossman JD Fisher 1997 Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions: New Approaches to Brain Tumor Therapy Central Nervous System Consortium J Clin Oncol 15 3121 3128 9294475 1:CAS:528:DyaK2sXmt1Sqtrs%3D An original article that demonstrates an important interaction between CYP450-inducing anti-epileptic drugs and the cytotoxic chemotherapeutic agent paclitaxel FetellMR, Grossman SA, Fisher JD, et al.: Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions: New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol 1997, 15:3121–3128. An original article that demonstrates an important interaction between CYP450-inducing anti-epileptic drugs and the cytotoxic chemotherapeutic agent paclitaxel.
54. 54. SA Grossman F Hochberg Fisher 1998 Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants Cancer Chemother Pharmacol 42 118 126 9654111 10.1007/s002800050794 1:CAS:528:DyaK1cXjslWmur0%3D Grossman SA, Hochberg F, Fisher, et al.: Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. Cancer Chemother Pharmacol 1998, 42:118–126.
55. 55. K Villikka KT Kivisto H Maenpaa 1999 Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors Clin Pharmacol Ther 66 589 593 10613614 1:CAS:528:DC%2BD3cXlsVanuw%3D%3D Villikka K, Kivisto KT, Maenpaa H, et al.: Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther 1999, 66:589–593.
56. 56. DK Baker MV Relling CH Pui 1992 Increased teniposide clearance with concomitant anticonvulsant therapy J Clin Oncol 10 311 315 1732431 1:STN:280:DyaK387itF2ntg%3D%3D Baker DK, Relling MV, Pui CH, et al.: Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol 1992, 10:311–315.
57. 57. HS Friedman WP Petros AH Friedman 1999 Irinotecan therapy in adults with recurrent or progressive malignant glioma J Clin Oncol 17 1516 1525 10334539 1:CAS:528:DyaK1MXjsF2ms7o%3D Friedman HS, Petros WP, Friedman AH, et al.: Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999, 17:1516–1525.
58. 58. CSM Straathof MJ Bent van den J Ma 1998 The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor J Neuro-Oncol 37 1 8 10.1023/A:1005835212246 1:STN:280:DyaK1c7osVOntA%3D%3D Straathof CSM, van den Bent MJ, Ma J, et al.: The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor. J Neuro-Oncol 1998, 37:1–8.
59. 59. CSM Straathof Bent van den WJ Loos 1999 The accumulation of topotecan in 9L glioma and in the brain parenchyma with and without dexamethasone administration Neuro-Oncol 42 117 122 10.1023/A:1006166716683 1:STN:280:DyaK1MzkslCitQ%3D%3D Straathof CSM, van den Bent, Loos WJ, et al.: The accumulation of topotecan in 9L glioma and in the brain parenchyma with and without dexamethasone administration. Neuro-Oncol 1999, 42:117–122.
60. 60. EG Brain LJ Yu K Gustafsson 1998 Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo Br J Cancer 77 1768 1776 9667645 1:CAS:528:DyaK1cXktVCmsLk%3D Brain EG, Yu LJ, Gustafsson K, et al.: Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo. Br J Cancer 1998, 77:1768–1776.
61. 61. CD Anderson J Wang GN Kumar 1995 Dexamethasone induction of taxol metabolism in the rat Drug Metab Dispos 23 1286 1290 8591732 1:CAS:528:DyaK2MXpsFKms7w%3D Anderson CD, Wang J, Kumar GN, et al.: Dexamethasone induction of taxol metabolism in the rat. Drug Metab Dispos 1995, 23:1286–1290.
62. 62. C Crone 1986 The blood-brain barrier: a modified tight epithelium AJ Suckling MG Rumsby MWB Bradbury The Blood-Brain Barrier in Health and Disease Ellis Horwood Chichester, England 17 17 Crone C: The blood-brain barrier: a modified tight epithelium. In The Blood-Brain Barrier in Health and Disease. Edited by Suckling AJ, Rumsby MG, Bradbury MWB. Chichester, England: Ellis Horwood; 1986:17.
63. 63. RA Fishman 1992 Cerebrospinal Fluid in Diseases of the Nervous System WB Saunders Philadelphia Fishman, RA: Cerebrospinal Fluid in Diseases of the Nervous System, edn 2. Philadelphia: WB Saunders; 1992.